frovatriptan succinate

Also found in: Dictionary.

frovatriptan succinate

Frova, Migard (UK)

Pharmacologic class: Serotonin 5-hydroxytryptamine (5-HT)1-receptor agonist

Therapeutic class: Antimigraine agent

Pregnancy risk category C


Binds selectively to serotonin receptors on cranial arteries, causing vasoconstriction and decreased blood flow


Tablets: 2.5 mg

Indications and dosages

Acute migraine

Adults: 2.5 mg P.O. as a single dose at first symptom of migraine. If migraine returns, may repeat after 2 hours. Maximum of three doses in 24 hours (7.5 mg/day).


• Hypersensitivity to drug or its components

• Cerebrovascular disorders

• Ischemic heart disease or history of myocardial infarction

• Uncontrolled hypertension

• Peripheral vascular disease

• Hemiplegic or basilar migraine

• Within 24 hours of another 5-HT1-receptor agonist or ergotamine-containing or ergot-type drug


Use cautiously in:

• patients receiving selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)

• pregnant or breastfeeding patients

• children (safety and efficacy not established).


• Give one tablet with plenty of fluids at first symptom of migraine.

• If headache returns, administer another tablet after 2 hours.

• Don't exceed three tablets in 24-hour period.

• Give first dose under close supervision if patient has coronary artery disease or other risk factors.

• Don't give within 24 hours of another 5-HT1-receptor agonist or ergotamine-containing or ergot-type drug.

Adverse reactions

CNS: dizziness, headache, anxiety, malaise, fatigue, weakness, drowsiness, paresthesia, sensation loss

CV: palpitations, tightness in chest, myocardial infarction (MI)

EENT: abnormal vision, tinnitus, rhinitis

GI: nausea, diarrhea, dyspepsia, abdominal pain

Musculoskeletal: skeletal or muscle pain

Skin: flushing, diaphoresis, photosensitivity

Other: altered taste, hot or cold sensations


Drug-drug. Ergot alkaloids, other serotonin 5-HT1-receptor agonists: prolonged vasoactive reactions

Hormonal contraceptives, propranolol: increased frovatriptan bioavailability

SSRIs, SNRIs: serotonin syndrome (including mental status changes, hyperreflexia, nausea, vomiting)

Drug-behaviors. Sun exposure: increased risk of photosensitivity

Patient monitoring

• Assess for cardiovascular reactions, especially signs and symptoms of MI.

• Monitor neurologic status, particularly for indications of cerebrovascular accident.

• Check for rash and itching.

Patient teaching

• Instruct patient to take one tablet with plenty of fluids at first symptom of migraine.

• Tell patient he may take second tablet 2 hours after first if migraine returns.

Advise patient to immediately report chest pain.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved
Mentioned in ?
References in periodicals archive ?
According to IMS Health, sales of Frovatriptan Succinate Tablets 2.5 mg sales reached approximately USD88.3m in the 12 months ending 31 March 2016.
Pharmaceutical company Mylan (NasdaqGS:MYL) said on Friday that the federal district court has granted its request to enforce a settlement agreement with Endo Pharmaceuticals for Frovatriptan Succinate Tablets, 2.5 mg.
Endo Pharmaceuticals Holdings Inc., for example, has submitted a supplemental new drug application for Frova (frovatriptan succinate) 2.5-mg tablets for the short-term (six days per month) prevention of menstrual migraine (MM).
Pharmaceutical company Mylan Inc (Nasdaq:MYL) said on Wednesday that it has been sued in connection with the filing of an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for Frovatriptan Succinate EQ, 2.5 mg base tablets.